1. ¹Division of Experimental Diabetes and Aging, Mount Sinai School of Medicine, New York, New York, USA
2. ²Department of Physiology and Pathophysiology, Peking (Beijing) University Health Science Center, Beijing, China
3. ³Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Correspondence: Y Guan, Department of Physiology and Pathophysiology, 38 Xueyuan Road, Peking University Diabetes Center, Peking (Beijing) University Health Science Center, 100083 Beijing, China. E-mail: youfeiguan@bjmu.edu.cn

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.